Skip to content
In Stock Zomig
Migraine

Zomig

Patients aged 18 years and older with an acute migraine attack may be prescribed Zomig nasal spray. Its active ingredient, zolmitriptan, belongs to the triptan class and targets migraine pain rather…

Guaranteed quality Original product
Delivery: from 4 days Discreet shipping
24/7 Support Always available
Active ingredient: Zolmitriptan
Select pack Package Per unit Price
$ 250.98 $ 250.98
Free Regular Delivery $ 183.34 $ 501.96 $ 366.68 Save 27%
Free Regular Delivery $ 161.98 $ 752.94 $ 485.94 Save 35%
Free Express Delivery $ 151.30 $ 1,003.92 $ 605.20 Save 40%
Best value Free Express Delivery $ 144.54 $ 1,254.90 $ 722.68 Save 42%

Free delivery on orders from $ 356.00, free express delivery from $ 534.00

Secure payment methods:
VISA AMEX JCB DISCOVER

Patients aged 18 years and older with an acute migraine attack may be prescribed Zomig nasal spray. Its active ingredient, zolmitriptan, belongs to the triptan class and targets migraine pain rather than preventing future attacks.

Product information

Zomig contains zolmitriptan, a selective serotonin 5-HT1B/1D receptor agonist used for the acute treatment of migraine with or without aura. It is intended for an active migraine episode, not for routine daily prevention. The nasal spray delivers zolmitriptan through the nasal lining, which can be useful when migraine-related nausea or vomiting makes swallowing difficult.

Ingredients

The product form is a nasal spray containing zolmitriptan 2.5 mg. It is supplied in bottles designed for intranasal administration.

The formulation is intended for an individual migraine episode. It is not a daily nasal medicine, a preventative spray, or a treatment for sinus congestion.

Presentation Active ingredient Route
Zomig nasal spray 2.5 mg Zolmitriptan Intranasal

Zolmitriptan may be used when swallowing is difficult because of nausea. The nasal route can also provide an alternative for patients who have previously struggled to keep oral migraine treatment down.

Therapeutic indications

The 2.5 mg spray can also help associated symptoms such as nausea when used early in an attack.

Directions for use

Use Zomig nasal spray at the beginning of the headache phase of a migraine attack. The spray is administered into one nostril according to the prescribed instructions. The device should not be directed toward the eyes or used as a substitute for a regular nasal decongestant.

Clinical dosing commonly begins with one 2.5 mg nasal spray. If the migraine improves and then returns, or if the first dose gives insufficient relief, a second dose may be prescribed after an interval of at least two hours. The total amount used in 24 hours must remain within the prescribed maximum. The dose is decided individually, taking age, other medicines, and health conditions into account.

A missed dose is not usually relevant because Zomig is used for individual attacks rather than on a fixed daily schedule. Do not use extra sprays to compensate for delayed treatment. Follow the individual regimen established for your migraine pattern.

The Australian Therapeutic Goods Administration recognises the need for dose selection based on patient factors, migraine response, and cardiovascular risk [2].

Before spraying, breathe gently through the mouth and avoid forceful sniffing. Strong inhalation can make the medicine run down the throat and leave an unpleasant taste.

Common administration mistakes include using the spray repeatedly within a short period, treating several unrelated headaches without reviewing the pattern, or combining it with another triptan. Frequent use of acute migraine medicines can also contribute to medication-overuse headache.

If migraine attacks require acute treatment on many days each month, the treatment plan may need adjustment. A headache diary can record the date, symptoms, trigger pattern, time of spraying, relief, and any second dose. This gives a prescriber useful information without relying on memory during a busy consultation.

When not to use it

Zomig is not intended for people with certain cardiovascular or cerebrovascular conditions, and a medical history review is needed before treatment.

Medicines requiring specific review

Monoamine oxidase-A inhibitors can increase zolmitriptan exposure. Zomig should not be used with an MAO-A inhibitor or within the interval specified by the prescribing information.

Selective serotonin reuptake inhibitors, serotonin-noradrenaline reuptake inhibitors, tricyclic antidepressants, lithium, tramadol, and St John’s wort may increase serotonergic effects. The combination is not automatically prohibited in every case, but it requires a clear medication review and awareness of serotonin-syndrome symptoms.

Cimetidine and some CYP1A2 inhibitors may alter zolmitriptan concentrations. A prescriber should also review medicines used for blood pressure, depression, pain, and other migraine treatments.

Pregnancy and breastfeeding require individual assessment. The decision depends on migraine severity, alternatives, pregnancy stage, and the amount of treatment needed. The WHO describes migraine treatment in pregnancy as a risk–benefit decision rather than a routine self-treatment choice [3].

When this is not for you

Zomig is not suitable for everyone. It is not intended for people with certain cardiovascular or cerebrovascular conditions, and a medical history review is needed before treatment.

Pregnancy and breastfeeding require individual assessment. The decision depends on migraine severity, alternatives, pregnancy stage, and the amount of treatment needed.

Unwanted effects

The most frequently reported reactions to zolmitriptan include an unusual taste, tingling, dizziness, sleepiness, warmth, pressure, or tightness in the throat, chest, neck, or jaw. These sensations are often short-lived, but chest or throat symptoms must not be dismissed when they are intense, persistent, or accompanied by breathlessness.

Nasal administration can produce local effects such as irritation, altered taste, or discomfort inside the nose. A bitter taste after spraying is common with medicines delivered through the nasal passage and does not necessarily mean the dose was lost.

The FDA label reports that many adverse effects are mild to moderate and temporary, though serious cardiovascular reactions have been reported rarely [1].

Seek urgent medical assessment for:

  • Severe or persistent chest pain.
  • Fainting, marked shortness of breath, or an irregular heartbeat.
  • Sudden weakness, facial drooping, confusion, or difficulty speaking.
  • Severe abdominal pain or bloody diarrhoea.
  • Swelling of the lips, tongue, or throat.
  • Widespread rash with breathing difficulty.

Serotonin syndrome can cause agitation, sweating, fever, diarrhoea, tremor, muscle stiffness, and a fast heartbeat. It is uncommon, yet the risk increases when several serotonergic medicines are combined.

A brief bitter taste can occur after nasal dosing. Persistent chest pressure, faintness, or breathing difficulty is different and needs urgent medical attention.

Patients sometimes mistake mild warmth or tingling for an allergic reaction. Allergy is more likely when swelling, hives, wheezing, or rapidly worsening breathing symptoms appear. A prescriber can help distinguish a transient triptan sensation from a clinically serious reaction.

Mechanism of action

Zolmitriptan is a triptan. Triptans activate specific serotonin receptors, mainly 5-HT1B and 5-HT1D receptors, in blood vessels and nerve endings involved in migraine. This reduces signalling from the trigeminal nerve and narrows blood vessels that have become dilated during the attack.

The result is a reduction in migraine pain and related symptoms. Nausea and vomiting may improve as the underlying migraine process settles, although Zomig is not a general anti-nausea medicine and does not treat vomiting from unrelated causes.

Zolmitriptan differs from paracetamol and anti-inflammatory pain relievers because it is designed to act on migraine-specific pathways. It also differs from preventive medicines, which are taken regularly to reduce the number of attacks over time.

The FDA prescribing information describes zolmitriptan nasal spray as an acute migraine treatment, while the European Medicines Agency provides the wider regulatory framework for triptan safety and use [1]. Cardiovascular screening is relevant because serotonin receptors targeted by triptans also exist in blood vessels outside the brain.

Common mistakes

Several patterns can reduce benefit or increase risk:

  • Using Zomig for a non-migraine headache.
  • Waiting until the attack is severe before treating.
  • Taking a second spray sooner than prescribed.
  • Combining Zomig with another triptan.
  • Forgetting to mention antidepressants or St John’s wort.
  • Continuing frequent acute treatment without reviewing medication-overuse headache.
  • Assuming nasal administration removes cardiovascular precautions.
  • Using the device for nasal congestion rather than migraine.
  • Ignoring repeated chest pressure because it occurred after previous doses.
  • Treating a new neurological symptom as a familiar aura without assessment.

A headache diary can reveal whether the treatment is helping. Record headache days, migraine features, time of administration, relief within the first few hours, recurrence, and adverse effects.

One useful detail is the difference between treatment failure and recurrence. If the pain never improves, the dose may not have worked or the diagnosis may need review. If pain improves and returns later, the attack may have recurred and the prescribed repeat-dose plan becomes relevant.

Comparison

Zomig has a migraine-specific mechanism. Other approaches may be chosen according to cardiovascular history, nausea, previous response, and the need for a non-triptan option.

Approach Main role Key limitation
Zolmitriptan nasal spray Acute migraine treatment through 5-HT1B/1D activity Unsuitable for some cardiovascular conditions
Other triptans, such as sumatriptan Acute migraine treatment through a similar receptor pathway Response and tolerability vary between patients
Non-triptan analgesic approach Pain relief through non-triptan mechanisms May be less suitable for severe or rapidly escalating migraine

Sumatriptan is the closest comparison by drug class, while zolmitriptan may suit a patient who needs a nasal route or has had an inadequate response to another triptan. One triptan should not be combined with another during the same period unless a prescriber has given specific instructions.

Anti-inflammatory medicines may be used for some migraine attacks, yet they bring their own risks, including gastrointestinal bleeding, kidney effects, and blood-pressure concerns in susceptible patients. The best option depends on the person’s diagnosis, attack pattern, medical history, and previous treatment response.

What doctors say

Doctors generally assess three issues before prescribing a triptan: whether the symptoms represent migraine, whether cardiovascular risk is acceptable, and whether the patient can use the medicine without exceeding recommended frequency.

A clinician may ask about chest symptoms during exercise, smoking, diabetes, high blood pressure, cholesterol, family history of early heart disease, and previous stroke. These questions are relevant because triptans constrict certain blood vessels as part of their therapeutic action.

The expected result is meaningful relief from the current attack, not guaranteed elimination of every symptom. Some patients respond to the first dose; others need a different triptan, a second dose when permitted, or a preventive strategy because attacks are frequent.

Migraine that changes character needs reassessment. A sudden maximal headache, fever with neck stiffness, new neurological deficit, or headache after head injury requires urgent medical evaluation rather than repeated use of Zomig.

What customers often ask

Can older adults use Zomig?

Older adults may require a more careful cardiovascular review before receiving zolmitriptan. Blood pressure, heart disease, circulation problems, kidney or liver function, and other medicines can influence the treatment choice. Australian TGA prescribing principles from 2024 support individual dose selection, especially when age and comorbidities affect medicine handling. A 65-year-old with new migraine symptoms also needs diagnostic review because a first or changed headache pattern should not automatically be treated as an established migraine. The prescriber should confirm the diagnosis before selecting acute treatment.

How does Zomig differ from sumatriptan?

Zomig contains zolmitriptan, while sumatriptan contains a different active substance. Both belong to the triptan class and act on related serotonin receptors, yet individual response, side effects, onset, and preferred route can differ. The EMA (2024) describes triptans as migraine-specific acute treatments rather than general painkillers. A patient who responds poorly to one triptan may respond better to another, but triptans should not be combined without explicit prescribing instructions.

Can Zomig be used during pregnancy or breastfeeding?

Pregnancy and breastfeeding require a personalised assessment before zolmitriptan is used. The decision considers migraine severity, previous response, pregnancy stage, breastfeeding status, and available alternatives. WHO clinical principles from 2022 support minimising unnecessary medicine exposure while treating disabling symptoms appropriately. Do not start, repeat, or stop migraine treatment during pregnancy based only on a previous routine because the clinical circumstances may have changed.

Do diet, exercise, or daily habits affect migraine response?

Regular sleep, adequate hydration, consistent meals, and moderate caffeine intake may reduce common migraine triggers for some people. Exercise can help general migraine management, though sudden intense exertion may trigger an attack in susceptible patients. The American Headache Society's 2024 guidance recognises lifestyle regularity as part of migraine care, while Zomig remains an acute treatment rather than a substitute for prevention. Alcohol, dehydration, skipped meals, and irregular sleep can make attacks harder to control.

What should happen if the expected relief does not come?

Do not keep repeating sprays beyond the prescribed limit when the first dose fails. A persistent or unusual headache may represent a different diagnosis, an unsuitable treatment plan, or a complication requiring assessment. NICE migraine guidance from 2021 supports reviewing diagnosis, acute-treatment timing, frequency of use, and preventive options when attacks remain inadequately controlled. Emergency care is needed for sudden severe headache, new weakness, speech difficulty, fainting, or severe chest symptoms.

How soon can the effect of Zomig become noticeable?

Nasal zolmitriptan is designed for relatively rapid absorption compared with a swallowed medicine, although the timing of relief varies between patients and attacks. Some people notice improvement during the first hour, while others need longer for pain and associated symptoms to settle. The FDA's 2019 prescribing information evaluates response during the early hours after administration and supports use during the acute attack. If treatment repeatedly gives no meaningful improvement, the regimen should be reviewed rather than escalated independently.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Sources

  1. U.S. Food and Drug Administration (2019). Zomig (zolmitriptan) Nasal Spray Prescribing Information.
  2. Therapeutic Goods Administration (2024). Australian Product Information: Zomig Nasal Spray.
  3. World Health Organization (2011). Atlas of headache disorders and resources in the world 2011.

How Buyers Rate Zomig

Based on 3 reviews

Matthew, 29 Verified
Rating: 5 out of 5

I used the 2.5 mg nasal spray near the start of a migraine. The pain eased within a couple of hours, although I noticed a bitter taste and felt slightly sleepy afterwards. The nasal route was easier than swallowing during nausea.

5 Nov 2026
Tom F., 65 Verified
Rating: 4 out of 5

Zomig helped one attack, but I felt pressure across my chest that lasted longer than I expected. I stopped using further doses until my doctor reviewed my heart and blood-pressure history. The migraine relief was useful, but the sensation was not something I wanted to ignore.

7 Oct 2026
Simon R., 66 Verified
Rating: 3.5 out of 5

The spray reduced the headache and light sensitivity during the first few attacks. It did not work as well when I waited several hours, and the bitter taste was unpleasant. Keeping a written record helped me explain the timing to my prescriber.

21 Oct 2026
Get our free app Shop faster and track your orders 3.8 · 491 reviews Install